Background/Aims: This study investigates the ameliorative effect of concurrent and pretreatment with angiotensin II receptor blocker, losartan (LOS), against gentamicin (GEN)-induced renal damage.Methods: Rats were divided into five groups: control, LOS group (10 mg/kg/day for 7 days), GEN group (100 mg/kg/day for 7 days), GEN + LOS pretreated group (treated with LOS for 7 days followed by 7 days of GEN), and GEN + LOS concurrently treated group (simultaneously treated with GEN and LOS for 7 days). Results: Concurrent treatment with LOS significantly reduced urine volume, microalbuminuria, blood urea nitrogen (BUN) and serum creatinine levels elevated by GEN administration. Also, LOS significantly attenuated GEN-induced increase in malondialdehyde and decrease in reduced glutathione, and catalase and superoxide dismutase activities in renal cortical homogenates. Additionally, histopathological examination and scoring showed that LOS markedly ameliorated GEN-induced renal tubular damage. Conversely, pretreatment with LOS produced no significant changes in urine volume, microalbuminuria, BUN and serum creatinine with little changes in the oxidative stress parameters when compared with the GEN-treated group. Conclusion: Concurrent treatment with LOS has produced marked amelioration in biochemical indices and oxidative stress parameters against GEN-induced nephrotoxicity. Accordingly, LOS can be considered a feasible antihypertensive drug for hypertensive patients simultaneously treated with GEN.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.